4 citations
,
April 2001 in “European journal of cancer” Scalp cooling prevented hair loss in half of the patients, despite significant side effects.
1 citations
,
June 2023 in “Sciential - McMaster Undergraduate Science Journal” This paper reviews scalp cooling as an effective method for preventing chemotherapy-induced alopecia, highlighting recent trials that demonstrate its ability to preserve and regrow hair, thus improving patient well-being.
This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.
25 citations
,
March 2018 in “Journal of oncology practice” This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.
2 citations
,
December 2013 in “Cancer Research” This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.